Amgen's Uplizna Gets EU Nod: Stock Jumps
Update: 2025-09-19
Description
Amgen's stock jumped 3.5% after EU regulators recommended approving Uplizna for a rare autoimmune disorder with no current treatments. A successful Phase 3 trial showed significant remission rates, boosting investor confidence and highlighting the power of regulatory wins for even stable companies.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
